Felzartamab plus lenalidomide–dexamethasone versus lenalidomide–dexamethasone for relapsed or refractory multiple myeloma: an open-label, parallel-controlled, randomised, phase 3 trial
Felzartamab plus lenalidomide–dexamethasone versus lenalidomide–dexamethasone for relapsed or refractory multiple myeloma: an open-label, parallel-controlled, randomised, phase 3 trial. // The Lancet Haematology. – URL: https://www.sciencedirect.com/science/article/pii/S2352302626002231?dgcid=rss_sd_all
Felzartamab plus lenalidomide–dexamethasone versus lenalidomide–dexamethasone for relapsed or refractory multiple myeloma: an open-label, parallel-controlled, randomised, phase 3 trial. The Lancet Haematology. https://www.sciencedirect.com/science/article/pii/S2352302626002231?dgcid=rss_sd_all
“Felzartamab plus lenalidomide–dexamethasone versus lenalidomide–dexamethasone for relapsed or refractory multiple myeloma: an open-label, parallel-controlled, randomised, phase 3 trial.” The Lancet Haematology.
@article{article68521,
title = {Felzartamab plus lenalidomide–dexamethasone versus lenalidomide–dexamethasone for relapsed or refractory multiple myeloma: an open-label, parallel-controlled, randomised, phase 3 trial},
journal = {The Lancet Haematology},
url = {https://www.sciencedirect.com/science/article/pii/S2352302626002231?dgcid=rss_sd_all}
}